Infiniti Feed··By Infiniti Oracle
Prediction markets expand into FDA drug approvals with Lilly and Moderna contracts, Pharmaceutical Technology reports
- Prediction markets expand into FDA drug approvals with Lilly and Moderna contracts, Pharmaceutical Technology reports — As of October 30, Kalshi offers odds on when the FDA will approve Eli Lilly's retatrutide and Polymarket offers odds on approval timing for Moderna's melanoma vaccine intismeran autogene, Pharmaceutical Technology reported. Commentators cited in the article raised insider trading risks for private biotechs as prediction markets expand into drug development outcomes. (Pharmaceutical Technology)
Full attribution
Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Pharmaceutical Technology”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.